GPT-Rosalind: The AI Scientist Changing Drug Discovery 🧬🚀
OpenAI unveiled GPT‑Rosalind, a frontier‑reasoning model built specifically for live scientific research in biology, drug discovery and translational medicine. Unlike a generic chatbot, it is engineered to think like a scientist, parsing complex protein, gene, chemical reaction and disease biology data. The model supports multi‑step workflows: literature review, hypothesis generation, experimental design, and data analysis. It can query and synthesize information from over fifty scientific tools and databases, turning raw data into actionable insights. Early adopters such as Amgen, Medtronic and Thermo Fisher are already testing the system within their R&D pipelines. OpenAI highlighted that GPT‑Rosalind can suggest new experiments and connect disparate datasets, effectively acting as a collaborative research partner. By automating routine analytical tasks, it promises to compress the typical 10‑15‑year drug development cycle. If the technology lives up to its promise, pharmaceutical companies could accelerate discovery, lower costs, and shift competitive advantage toward firms that integrate AI‑driven scientific collaboration.
Treating Heart Disease Behind Sudden Death in Young People | David Elsey
Cardiol Therapeutics used the interview to detail progress on its Maverick Phase III trial for recurrent pericarditis and the Archer Phase II study in myocarditis, while previewing its next‑generation drug CRD38 aimed at chronic heart‑failure inflammation. The Archer data, presented at the European...
Episode 16: Building AI for Life Sciences
The OpenAI Podcast’s Episode 16 spotlights the company’s new biochemistry‑focused model series, designed to embed advanced AI directly into life‑science research pipelines. Joy Jiao and Yunyun Wang explain how the models extend beyond text and code, offering mechanistic insights in...
Treating Colorectal & Rectal Cancer: Surgery, Radiation Therapy & Systemic Therapy
The session, held on the final day of National Colorectal Cancer Awareness Month, introduced the latest surgical advances for colon, rectal and anal cancers. Dr. Isabelle Lilionic, an NYU colorectal surgeon, outlined anatomy, treatment goals and the shift from traditional...
Eradicating Leprosy Using Genetics
The video links a 2007‑08 excavation at Magdalin Hill near Winchester, where paleopathologists identified unmistakable leprosy lesions in skeletal remains, to today’s fight against the disease. Leprosy still generates roughly 200,000 new infections annually, and the World Health Organization has set...
What It Takes to Turn Academic Research Into a Venture-Backed StartupBM S2E9 FULL EDIT
The episode follows Capella Kurst, Stanford PhD‑turned‑founder, as she transforms a bio‑inspired dry adhesive from a university lab into Gecko Materials, a venture‑backed startup now operating on the International Space Station and serving semiconductor, automotive and robotics customers. Key insights...
The 60-Year Cholesterol War Is Finally Over
The video chronicles the resolution of a six‑decade debate over cholesterol management, tracing its origins to a 2006 Dallas Heart Study discovery of a woman with an LDL of 14 mg/dL caused by PCSK9 loss‑of‑function mutations. Researchers realized that silencing PCSK9...
AI Just Compressed 160 Years of Aging Research — Here's What They Found | Dr. David Sinclair
In a recent interview, Dr. David Sinclair explained how artificial intelligence is reshaping his lab’s quest to reverse human aging. By leveraging AI‑driven virtual screening, his team evaluated roughly eight billion synthetic molecules, seeking a single compound that could replicate the...
NEJM Clinician: Catheter-Directed PE Treatment: Does It Deliver?
The New England Journal of Medicine reports a multinational randomized trial evaluating catheter‑directed fibrinolysis (CDT) versus standard anticoagulation in patients with intermediate‑risk (sub‑massive) pulmonary embolism. Over 500 participants were assigned to low‑dose, catheter‑delivered clot‑busting therapy or anticoagulation alone, with the...
Scaling Innovative Clinical Trial Approaches: Challenges, Progress, and Opportunities
The FDA’s Center for Clinical Trial Innovation (C3TI), together with the Duke‑Margolis Institute, convened a hybrid workshop to assess progress in clinical‑trial innovation. The event showcased the C3TI Demonstration Program, which is funded by a $5.19 million FDA/HHS award, and examined...
Aloe Blacc’s Fame Means Nothing in Biotech (and That’s the Point) | Equity Podcast
The Equity Tech Crunch podcast features Grammy‑nominated singer‑songwriter Aloe Blacc, who has transitioned from music to biotech entrepreneurship. He co‑founded Major Inc. and its spin‑off Pepto ID to develop novel cancer therapies, focusing on pancreatic cancer, a disease with a 90 %...
2026 ISPE AI in Life Sciences Summit: Why This Event Matters
The 2026 ISPE AI in Life Sciences Summit positions artificial intelligence as a transformative force comparable to the advent of the first computers or smartphones, promising a clear before‑and‑after for the pharmaceutical sector. Organizers stress that deploying AI responsibly—while safeguarding patient...
HVIVO: Beating the Odds in 2025 - and Why 2026 Looks Better Still
hVIVO PLC released its full‑year 2025 results, highlighting £47 million of revenue and a modest £1 million positive EBITDA—both in line with the guidance issued earlier in the year. The company closed the year with just over £40 million in cash, positioning it...
Plant Tissue Culture Techniques Csir Net Life Sciences | Plant Tissue Culture Basics
The video introduces plant tissue culture as a technique that isolates meristematic explants, sterilizes them, and places them on a defined growth medium under controlled temperature, pH, light and gas conditions. By supplying carbon sources, macro‑ and micronutrients, and precise...
Dr. Glaucomflecken Explains: Tecovirimat for the Treatment of Mpox (STOMP/A5418)
The video features Dr. Glaucomflecken reviewing a New England Journal of Medicine study that evaluated oral tecovirimat, an antiviral approved for smallpox, as a treatment for mpox. The randomized, placebo‑controlled trial enrolled adults with presumptive or laboratory‑confirmed clade 2 mpox within...
NIH SciBites: Turning Down the Dial on Hearing Loss
The video features Jack, a post‑baccalaureate fellow at the NIH, describing his lab’s effort to curb noise‑induced hearing loss, a condition that stems from chronic exposure to everyday sounds and is currently irreversible. He explains that while brief, extremely loud bursts...
HVIVO Lands Influenza Trial Deal
Human Vaccines Online (HVO) announced a contract with biotech partner Trrow to run a prophylactic antiviral challenge study against influenza, leveraging its newly engineered H1N1, H3N2 and B virus panel. The study will enroll roughly 150 healthy volunteers in China, using...
What Most Favored Nation Drug Pricing Would Mean for the US
The video examines the most‑favored‑nation (MFN) drug‑pricing proposal that would tie U.S. prices to the lowest rates paid by other developed economies. Host Dr. James Robinson explains why the idea has gained political traction, especially after President Trump’s pledge to...
NIH-Led Research Discovers New Way Lung Cancer Can Emerge
The NIH‑led study unveiled a previously unknown pathway by which certain lung cancers develop, driven by retrotransposon elements—mobile DNA sequences that can copy and paste themselves throughout the genome. Using whole‑genome sequencing, researchers mapped mutational signatures that pointed to this...
Ozempic: $14 in India Vs. $349 in the US #shorts
The video highlights a stark price disparity for semaglutide, the active ingredient in Ozempic, which costs $349 a month in the United States but only about $14 in India. The difference stems from the recent expiration of the drug’s patent...
How Federated Learning Could Bridge Pharma’s Data Divide
The video examines how federated learning can close the data gap that separates pharmaceutical companies from public chemical repositories. Each firm’s historical medicinal‑chemistry records are unique, and the industry lacks negative toxicology and bioactivity data, making local predictive models unreliable...
The Role of Computational Models in Systems Biology (3 Minutes)
The video outlines how computational models are reshaping systems biology by turning massive, noisy omics datasets into actionable, testable phenotypes. It contrasts traditional reductionist experiments—limited to isolated components—with dense, hairball networks that capture emergent cellular behavior, arguing that new modeling...
Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
The interview with Dr. Sarfaraz Niazi, CEO of RNA Therapeutics, explores his decades‑long journey from academia to industry and his pivotal role in shaping the biosimilar landscape. He recounts early work on biological drugs before the FDA had a formal...
Glioblastoma, ecDNA & Targeted Therapy - The Verhaak Lab at Yale School of Medicine
The Verhaak Lab at Yale School of Medicine presented research on extrachromosomal circular DNA (ecDNA) in glioblastoma, explaining how these small DNA loops differ from the linear chromosomes that normally house genetic material. The team showed that ecDNA enables tumor cells...
Former Sen. Ben Sasse Shines the Spotlight on a Possible Breakthrough for Pancreatic Cancer
Former Republican Senator Ben Sasse has drawn attention to an experimental oral therapy from Revolution Medicines after being diagnosed with stage 4 pancreatic cancer, a disease with a 13 percent five‑year survival rate. His public endorsement underscores the urgency of finding effective...
Idiopathic Pulmonary Fibrosis - Treatment and New Hope
The video explains idiopathic pulmonary fibrosis (IPF) as a chronic, progressive scarring of lung tissue driven by repeated alveolar epithelial injury, not by inflammation. It reviews the evolution of treatment—from failed immunosuppressive regimens to the first antifibrotic agents, pirfenidone and...
Enveda CEO Viswa Colluru on Positive Phase 1b Results for ENV 294 Therapy
Enveda’s chief executive, Viswa Colluru, highlighted the company’s AI‑powered chemistry platform that flips traditional drug discovery on its head by mining billions of years of natural molecular diversity. The approach underpinned the Phase 1b trial of ENV294, an oral tablet for moderate‑to‑severe...
The Brain on MDMA Can Go Somewhere CBT Has Never Been Able to Reach | Rachel Yehuda: Full Interview
The interview with Dr. Rachel Yehuda explores why trauma endures far beyond the original event and how emerging psychedelic‑assisted treatments, especially MDMA, are reshaping PTSD care. Yehuda distinguishes stress—typically resolved by removing the stressor—from trauma, which acts as a lifelong watershed....
BioVie Targets Neuroinflammation and Insulin Resistance in Parkinson’s Treatment Approach
BioVie’s CEO Cuong Do explained the company’s hypothesis that Parkinson’s disease is driven not only by dopamine loss but also by neuroinflammation‑induced insulin resistance. The firm is developing Beziterim, a molecule designed to clear the “rust” on cellular insulin receptors,...
NanoViricides Files for Rare Pediatric Disease Designation for Measles Drug
NanoViricides announced that it has filed an FDA application for Rare Pediatric Disease designation for its investigational measles antiviral, NV‑387. The move positions the company to qualify for a Priority Review Voucher (PRV) if the drug receives approval, a mechanism...
Neuralink Is Giving Back Dignity to Those with ALS and Paralysis #neuralink
The video highlights Neuralink’s brain‑computer interface as a breakthrough for individuals living with ALS and severe paralysis, offering a level of independence previously unattainable. The presenter describes moving from reliance on caregivers and limited assistive technology to controlling devices simply...
This AI Designs Drugs in Minutes
On March 17, 2026, Andre Watson, a biomeaterials scientist and founder of Ligendal, released a preprint describing a new AI system that designs peptide drugs in minutes. The system, called Ligan Forge, uses a discrete diffusion model that learns the physics...
PTSD Hope: Solvonis Has Secured Two US Patents Strengthening Its PTSD Drug Programme
Solvonis Therapeutics PLC announced the issuance of two United States patents that protect its lead PTSD candidate, SVN-114. CEO Anthony Tennyson said the patents validate the underlying science and move the program closer to clinical milestones. The protection strengthens Solvonis’s...
Gene Therapy Breakthrough at Genflow Biosciences Reports Promising Long-Lasting Effects in Dogs
Genflow Biosciences Ltd announced that its SLAB gene‑therapy trial in dogs showed durable efficacy, with functional improvements still evident three months after a single dose. CEO Dr. Eric Leire said the persistence could enable a one‑time treatment model for sarcopenia...
Coiled Therapeutics Doubles Cancer Drug's Success Rate with Simple Dosing Change
Coiled Therapeutics announced that its lead oncology candidate AO‑252 doubled its clinical benefit rate from 40% to 80% after switching to a twice‑daily dosing regimen. The improvement is attributed to sustained drug exposure, enhancing its multimodal action on mitosis, DNA...
Media Briefing: Malaria Vaccines, Trends, and What’s Ahead
The Johns Hopkins Malaria Research Institute hosted a media briefing to assess the latest malaria vaccine rollouts, shifting disease trends, and evolving global health financing. Speakers highlighted that malaria remains endemic in 80 countries, with 280 million cases and 600 000 deaths...
Solvonis Therapeutics CEO Says Dual US Patent Win Strengthens PTSD Pipeline
Solvonis Therapeutics announced the award of two U.S. patents covering separate chemical series that underpin its PTSD drug program. The patents reinforce the company’s intellectual property and signal a shift from a single‑asset approach to a broader chemistry platform. CEO...
The Anti-Aging Supplement Scam (New Evidence)
The video exposes how the Interventions Testing Program (ITP) debunks popular anti‑aging supplement claims by subjecting them to triple‑site mouse trials, highlighting recent findings that overturn hype around products like Aazanthin and calcium‑alpha‑ketoglutarate (AKG). In 2023 the ITP reported a 12 %...
Medical Mystery: The Man Who Got Weaker When He Started Training
A 43‑year‑old man who began resistance training presented to the ER with a CK level of nearly 19,000 U/L, prompting a deep dive into statin‑associated muscle injury. The episode reviews the patient’s history, lab findings, and the final diagnosis, highlighting three...
Original Article: Left Atrial Appendage Closure in Afib (CLOSURE-AF)
The CLOSURE‑AF trial evaluated left atrial appendage (LAA) closure versus guideline‑directed medical therapy in over 2,000 high‑risk atrial fibrillation patients. After three years, the device strategy failed to meet the predefined non‑inferiority margin for a composite of stroke, systemic embolism,...
BSF Enterprise: Lab-Grown T-Rex Leather & The Future of Luxury Materials
BSF Enterprise unveiled the world’s first lab‑grown leather derived from a reconstructed Tyrannosaurus Rex skin, marking a bold step in bio‑engineered luxury materials. The company’s scaffold‑free tissue‑engineering platform lets cells generate their own extracellular matrix, eliminating synthetic scaffolds that can...
NEJM Clinician: Should We Hold GLP-1–Based Medications Before Upper Endoscopy?
Clinicians are debating whether to hold GLP‑1 receptor agonists before elective upper endoscopy, given these drugs’ known effect on gastric motility. A recent randomized trial published in JAMA Internal Medicine enrolled 60 patients on semaglutide or tirzepatide scheduled for routine...
Defining the Next Era of Health Innovation
MIT’s HEALS symposium opened with Provost Anantha Chandrakasan introducing biotech visionary Noubar Afeyan, who framed the event’s theme: moving from discovery to leadership in translation, policy, and ecosystem building. Afeyan emphasized that the next era of health innovation will be...
Medicus Pharma Submits Optimized Phase 2 Study Design for Teverelix
Medicus Pharma announced that it has submitted an optimized Phase 2 trial design to the FDA for Teverelix, its novel GnRH antagonist aimed at preventing relapse of acute urinary retention (AUR) in men with enlarged prostates. The new protocol pivots from...
BillionToOne Is Solving One of Biotech’s Hardest Problems
Billion to One is redefining molecular diagnostics by turning the needle‑in‑a‑haystack problem of rare DNA fragments into a tractable mathematical one. Its flagship prenatal test, now processing more than 600,000 samples a year and holding roughly 20% of the U.S....
How Animal Biology Is Shaping The Future of Medicine
The video explores how evolutionary biology and animal models—particularly companion‑animal gene therapy and hibernation physiology—are being leveraged to accelerate longevity research for humans. Rejuvenate Bio is testing AAV‑based gene therapies in dogs, reporting restored cardiac function, delayed renal decline, and improved...
Aging Can Be Slowed Down
The video discusses a July 2025 study from Korea University of Medicine that pinpointed the protein HMGB1 as a key circulating factor that accelerates aging when transferred via blood. Building on classic parabiosis experiments—young mice rejuvenated by old blood and vice‑versa—the...
Genomic Mutations, Treatment--Resistance & Prostate Cancer - The Deng Lab at Yale School of Medicine
Therapy resistance remains a major hurdle in prostate cancer, especially after initial success with hormone‑based treatments. The Deng Lab at Yale School of Medicine is dedicated to uncovering the molecular mechanisms that enable cancer cells to evade therapy. The team combines...
LogMAR and PRIMA Highlights in 90 Seconds
The video explains LogMAR, the logarithmic metric for visual acuity, and introduces PRIMA, a photovoltaic retinal prosthesis designed to restore central vision. LogMAR is the base‑10 logarithm of the minimum angle of resolution; a 0.1 increase corresponds to losing one...
Cellbricks Secures $10M
Berlin‑based Celicks announced a $10 million financing round aimed at accelerating its proprietary 3D bioprinting platform for vascularized tissue implants. The capital will fund the transition of its lead programs from pre‑clinical studies into early‑stage clinical trials, positioning the startup at...